Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents?

Table 2 Available data from the studies in extenso on the use of direct-acting antiviral agents in the post-liver transplantation setting

	Pungpapong et al[44]	Coilly et al[45]	Werner et al[46]	Werner et al[48]
Patients (n)	60	37	9	14
Baseline characteristics
Regimen (n)
TLV	35	19	9	14
BCV	25	18	0	0
Four-week lead-in phase	100%	100%	0%	0%
IS therapy (n)
TAC	3	15	4	6
CSA	65	22	4	6
SIR	1	0	1	2
Fibrosis stage (n)
FO-F2	31	20	6	7
F3-F4	38	17	3	7
Cholestatic hepatitis (n)	NA	6	1	NA
Results
HCV-RNA negative
Week 4	NA	51% (19/37)	44% (4/9)	43% (6/14)
Week 8	NA	NA	NA	NA
Week 12	91% (55/60)	73% (27/37)	89% (8/9)	71% (10/14)
Week 24	56% (24/43)	NA	NA	57% (8/14)
Week 48	NA	61% (17/28)	NA	50% (7/14)
Adverse events
Hematological AEs
Anemia	93%	92%	66%	71%
Leukopenia	77%	40%	22%	36%
Thrombocytopenia	12%	32%	44%	64%
Infectious complication	12%	27%	11%	14%
Renal insufficiency	38%	13%	11%	7%
Acute rejection	5%	NA	0%	7%
Dermatological toxicity	10%	5%	33%	NA
Hepatic decompensation	12%	NA	0%	7%
Death	3%	8%	0%	7%

BCV: Boceprevir; TLV: Telaprevir; HCV: Hepatitis C virus; IS: Immunosuppressive; TAC: Tacrolimus; CSA: Cyclosporine; SIR: Sirolimus; NA: Not available.